Postinflammatory hyperpigmentation: A review of the epidemiology, clinical features, and treatment options in skin of color

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 7, 2010, Pages

  Davis, Erica C ^a   Callender, Valerie D ^a,b  

^a Callender Skin and Laser Center   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALPHA ARBUTIN; ARBUTIN; ASCORBIC ACID; AZELAIC ACID; COSMETIC; DEOXYARBUTIN; DEPIGMENTING AGENT; ENZYME INHIBITOR; FLUOCINOLONE ACETONIDE PLUS HYDROQUINONE PLUS TRETINOIN; GLYCOLIC ACID; GLYCOLIC ACID PLUS HYDROQUINONE PLUS TRETINOIN; GLYCYRRHIZA EXTRACT; HYDROQUINONE; ISOTRETINOIN; KLIGMAN FORMULA; KOJIC ACID; LIQUIRITIN; MEQUINOL; MEQUINOL PLUS RETINOIC ACID; N ACETYLGLUCOSAMINE; NICOTINAMIDE; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL; RETINOL PLUS SALICYLIC ACID PLUS SOY; SALICYLIC ACID; SUNSCREEN; TAZAROTENE; TRILUMA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHLOASMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT DERMATITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MIXTURE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INFLAMMATION; LEUKODERMA; LOW LEVEL LASER THERAPY; NAIL COLOR DEFECT; OCHRONOSIS; PATHOPHYSIOLOGY; POSTINFLAMMATORY HYPERPIGMENTATION; PREVALENCE; SKIN COLOR; SKIN PROTECTION;

EID: 77957565502     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Chang MW. Disorders of hyperpigmentation. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Elsevier Mosby; 2009:333-389.
2. Halder RM, Grimes PE, McLaurin CI, et al. Incidence of common dermatoses in a predominately black dermatologic practice. Cutis. 1983;32:388-390.
3. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80:387-394.
4. Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the national skin centre (Singapore) from 1989-1990. Int J Dermatol. 1992;31:555-559.
5. Taylor SC, Grimes PE, Lim J, et al. Postinflammatory Hyperpigmentation. J Cutan Med Surg. 2009;13:183-191.
6. Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl): S98-S106.
7. Alexander AM, Delph WI. Pseudofolliculitis barbae in the military. A medical, administrative and social problem. J Natl Med Assoc. 1974;66:459-464,479.
8. Edlich RF, Haines PC, Nichter LS, et al. Pseudofolliculitis barbae with keloids. J Emerg Med. 1986;4:283-286.
9. Perry PK, Cook-Bolden FE, Rahman Z, et al. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol. 2002;46(2 Suppl):S113-S119.
10. Grimes PE. Managment of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28: 77-85.
11. Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5: 357-361.
12. Ortonne J. Retinoic acid and pigment cells: a review of in-vitro and in-vivo studies. Br J Dermatol. 1992;127(Suppl 41):43-47.
13. Nordlund JJ, Abdel-Malek ZA. Mechanisms for post-inflammatory hyperpigmentation and hypopigmentation. In: Bagnara JT, ed. Advances in Pigment Cell Research: Proceedings of Symposia and Lectures from the Thirteenth International Pigment Cell Conference. Tucson, AZ; October 5-9, 1986. New York, NY: Liss; 1988:219-239.
14. Masu S, Seiji M. Pigmentary incontinence in fixed drug eruptions. Histologic and electron microscopic findings. J Am Acad Dermatol. 1983;8:525-532.
15. Lacz NL, Vafaie J, Kihiczac NI, et al. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;4:362-365.
16. Ruiz-Maldonado R, Orozco-Covarrubias ML. Post-inflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16:36-43.
17. Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17:184-195.
18. Hall HI, Rogers JD. Sun protection behaviors among African Americans. Ethn Dis. 1999;9:126-131.
19. Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: six years' experience with xeroderma pigmentosum. J Am Acad Dermatol. 1997;37:942-947.
20. Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol. 2009;161:732-736.
21. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalance and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2002;76:187-192.
22. Position Statement on Vitamin D. American Academy of Dermatology. November 14, 2009. http://www.aad.org/forms/policies/Uploads/PS/PS-Vitamin%20D%2011-16-09.pdf. Accessed on March 17, 2010.
23. Badreshia-Bansal S, Draelos ZD. Insight into skin lightening cosmeceuticals for women of Color. J Drugs Dermatol. 2007;6:32-39.
24. Halder RM, Richards GM. Management of dyschromias in ethnic skin. Dermatol Ther. 2004;17:151-157.
25. Palumbo A, d'Ischia M, Misuraca G, et al. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991;1073:85-90.
26. Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis. 2008;81:365-371.
27. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74: 362-368.
28. Jimbow K, Minamitsuji Y. Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther. 2001;14: 35-45.
29. Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697-703.
30. Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77:177-184.
31. Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75:57-62.
32. Cestari CF, Hassun K, Sittart A, et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007;6:36-39.
33. Hexsel D, Sidou F, Kerrouche N, et al. Combination of a triple combination cream and tretinoin cream in subjects with mottled hyperpigmentation associated with photodamage [P3210]. J Am Acad Dermatol. 2010;62(Suppl 1):AB120.
34. Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin. 2005;23:209-226.
35. Katsambas AD. RALGA (Diacneal), a retinaldehyde and glcolyic acid association and postinflammatory hyperpigmentation in acne-a review. Dermatology. 2005;210(Suppl 1):39-45.
36. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2:213-217.
37. Levitt J. The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol. 2007;57:854-872.
38. Halder RM, Nandekar MA, Neal KW. Pigmentary disorders in pigmented skins. In: Halder RM, ed. Dermatology and Dermatological Therapy of Pigmented Skins. Boca Raton, FL: CRC/Taylor & Francis; 2006:91-114.
39. Fleischer AB, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42:459-467.
40. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308-313.
41. Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004;74:319-322.
42. Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol. 2006;5:239-244.
43. Taylor SC, Callender VD. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation [Abstract]. J Am Acad Dermatol. 2006;54(Suppl):AB194.
44. Callender VD. A small open-label study of a 2% 4-hydroxyanisole and 0.01% tretinoin solution for the treatment of postinflammatory hyperpigmentation [Poster]. J Am Acad Dermatol. 2004;50(Suppl):P175.
45. Piacquadio D, Farris P, Downie J, et al. Mequinol 2%/tretinoin 0.01% solution monotherapy and combination treatment of solar lentigines and postinflammatory hyperpigmentation [Poster]. J Am Acad Dermatol. 2004;52(Suppl):P145.
46. Kuenzli S, Saurat JH. Retinoids. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Elsevier Mosby; 2009.
47. Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21:609-615.
48. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13:575-588.
49. Jacyk AK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68:48-54.
50. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45-50.
51. Winhoven SM, Ahmed I, Owen CM, et al. Postinflammatory hyperpigmentation in an Asian patient: a dramatic response to oral isotretinoin (13-cis-retinoic acid). Br J Dermatol. 2005;152:368-369.
52. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett. 2004;9:1-3.
53. Nguyen QH, Bui TP. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol. 1995;34:75-84.
54. Lowe NJ, Rizk D, Grimes P, et al. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20:945-959.
55. Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895.
56. Sarkar R, Bhalla M, Kanwar KJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002;205:249-254.
57. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58-61.
58. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282-284.
59. Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443-447.
60. Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32:9-13.
61. Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis. 1998;39:86.
62. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Inv Dermatol Symp Proc. 2008;13:20-24.
63. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996;276:765-769.
64. Funayama M, Arakawa H, Yamamoto R, et al. Effects of alpha- and beta-arbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem. 1995;59:134.
65. Boissy RE, Visscher M, deLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in-vivo skin lightening potency. Exp Dermatol. 2005;14:601-608.
66. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20-31.
67. Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide produces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004;26:231-238.
68. Kimball AB, Kaczvinsky JR, Li J, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol. Aug 28, 2009. [Epub ahead of print].
69. Bissett DL, Robinson LR, Raleigh PS, et al. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol. 2007;6:20-26.
70. Bolognia JL, Orlow SJ. Melanocyte Biology. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Elsevier Mosby; 2009.
71. Farris, PK. Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions. Dermatol Surg. 2005;31:814-818.
72. Shindo Y, Witt E, Hans D, et al. Enzymic and non-enzymic antioxidants in the epidermis and dermis of human skin. J Invest Dermatol. 1994;102:122-124.
73. Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol. 2003;48:866-874.
74. Kobayashi S, Takehana M, Itoh S, et al. Protective effect of magnesium-L-ascorbyl-2-phosphate against skin damage induced by UVB radiation. Photochem Photobiol. 1996;64:224-228.
75. Carcamo JM, Pedraza A, Borquez-Ojeda O, et al. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002;41:12995-30002.
76. Perricone NV. The photoprotective and anti-inflammatory effects of topical ascorbyl palmitate. J Geriatr Dermatol. 1993;1:5-10.
77. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43:604-607.
78. Kameyama K, Sakai C, Kondoh S, et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996;34:29-33.
79. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22:709-724.
80. Fu B, Li H, Wang X, et al. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem. 2005;53:7408-7414.
81. Yokota T, Nishio H, Kubota Y, et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 1998;11:355-361.
82. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39:299-301.
83. Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116:587-595.
84. Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. J Drugs Dermatol. 2007;6:917-922.
85. Hermanns JF, Petit L, Pierard-Franchimont C, et al. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology. 2002;204:281-286.
86. Finkey MB, Herndon J, Stephens T, et al. Soy moisturizer SPF 15 improves dyschromia [Poster]. J Am Acad Dermatol. 2005;52(Suppl):P170.
87. Sah A, Stephens TJ, Kurtz ES. Topical acne treatment improves postacne postinflammatory hyperpigmentation (PIH) in skin of color [Poster]. J Am Acad Dermatol. 2005;52(Suppl):P25.
88. Cosmetic Surgery National Databank Statistics. American Society for Aesthetic Plastic Surgery. http://www.surgery.org/download/2008stats.pdf. Accessed on May 30, 2009.
89. Grimes PE, Rendon MI, Pellerano J. Superficial chemical peels. In: Grimes PE, ed. Aesthetics and Cosmetic Surgery for Darker Skin Types. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:154-169.
90. Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther. 2004;17:196-205.
91. Sarkar R. Medium-depth chemical peels and deep chemical peels. In: Grimes PE, ed. Aesthetics and Cosmetic Surgery for Darker Skin Types. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:154-169.
92. Leu D, Yoo SS. Epidermal and color improvment in ethnic skin: microdermabrasion and superficial peels. In: Alam M, Bhatia AC, Kundu RV, Yoo SS, Chan HH, eds. Cosmetic Dermatology for Skin of Color. New York, NY: McGraw Hill; 2009:29-33.
93. Song JY, Kang HA, Kim MY, et al. Damage and recovery of skin barrier function after glycolic acid chemical peeling and crystal microdermabrasion. Dermatol Surg. 2004;30: 390-394.
94. Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients: a comparative study. Dermatol Surg. 1997;23: 171-174.
95. Ahn HH, Kim IH. Whitening effect of salicyclic acid peels in Asian patients. Dermatol Surg. 2006;32:372-375.
96. Grimes PE. The safety and efficacy of salicylic acid peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18-22.
97. Ejaz A, Raza N, Iftikhar N, et al. Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18:205-208.
98. Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. Dermatol Surg. 2004;30:385-388.
99. Alster TS, Tanzi EL. Laser surgery in dark skin. SKINmed. 2003;2:80-85.
100. Battle EF, Hobbs LM. Laser therapy on darker ethnic skin. Dermatol Clin. 2003;21:713-723.
101. Katz TM, Goldberg LH, Firoz BF, et al. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation. Dermatol Surg. 2009;35:1844-1848.
102. Terrell S, Aires D, Schweiger ES. Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patients. J Drugs Dermatol. 2009;8:669-671.
103. Cho SB, Park SJ, Kim JS, et al. Treatment of post-inflammatory hyperpigmentation using 1064-nm Q-switched Nd:YAG laser with low fluence: report of three cases. J Eur Acad Dermatol Venereol. 2009;23:1206-1207.
104. Antoniou C, Stefanaki C. Cosmetic camouflage. J Cosmet Dermatol. 2006;5:297-301.
105. Holme SA, Beattie PE, Fleming CJ. Cosmetic camouflage advice improves quality of life. Br J Dermatol. 2002;147: 946-949.
106. Kent G. Testing a model of disfigurement: effects of a skin camouflage service on well-being and appearance anxiety. Psychol Health. 2002;17:377-386.
107. Tanioka M, Miyachi Y. Camouflage for vitiligo. Dermatolog Ther. 2009;22:90-93.
108. Roberts NG, Nordlund JJ, Wright C. The corrective cover or camouflage clinic. Ear Nose Throat J. 1989;68:480-482.
109. Rayner VL. Camouflage therapy. Dermatol Clin. 1995;13: 467-472.
110. Katoulis AC, Alevizou A, Bozi E, et al. A randomized, double-blind, vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol. Oct 23, 2009. [Epub ahead of print].
111. Kasraee B, Handjani F, Parhizgar A, et al. Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology. 2005;211:360-362.
112. Choi S, Park YI, Lee SK, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002;27:513-515.
113. Tirado-Sanchez A, Santamaria-Roman A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol. 2009;48:893-895.
114. Choi YK, Rho YK, Yoo KH, et al. Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in vitro and in vivo. Int J Dermatol. 2010;49:218-226.
115. Comparative evaluation for the efficacy and tolerance of two skin products containing either hydroquinone or emblica extract with kojic acid in female subjects with facial dyschromia [Poster]. J Am Acad Dermatol. 2009;60(Suppl 1):AB24. [[AUTHOR: Please provide authors]]
116. Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol. 1999;16:6-11.
117. Child FJ, Fuller LC, Higgins EM, et al. A study of the spectrum of skin disease occurring in a black population in southeast London. Br J Dermatol. 1999;141:512-517.
118. Hartshorne, ST. Dermatological disorders in Johannesburg, South Africa. Clin Exp Dermatol. 2003;28:661-665.
119. Dunwell P, Rose A. Study of the skin disease spectrum occurring in an Afro-Caribbean population. Int J Dermatol. 2003;42:287-289.
120. Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin. 2003;21:689-697.
121. Arsouze A, Fitoussi C, Cabotin PP, et al. Presenting skin disorders in black Afro-Caribbean patients: a multicentre study conducted in the Paris region. Ann Dermatol Venereol. 2008;135:177-182.
122. El-Essawi D, Musial JL, Hammand A, et al. A survery of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol. 2007;56:933-938.